%0 Journal Article
%T Methylation of O6-methylguanine DNA methyltransferase promoter is a predictive biomarker in Chinese melanoma patients treated with alkylating agents
%A Chuangliang Cui
%A Huan Tang
%A Huan Yu
%A Jiayi Yu
%A Jie Dai
%A Jun Guo
%A Junya Yan
%A Lu Si
%A Lu Yang
%A Meng Ma
%A Tianxiao Xu
%A Xiaowen Wu
%A Xinan Sheng
%A Yan Kong
%A Zhihong Chi
%J SCIE-indexed Journal
%D 2018
%R 10.21037/21588
%X Melanoma is a highly aggressive skin cancer with high treatment resistance. Although the U.S. Food and Drug Administration (FDA) has approved various targeted therapies for melanoma which includes BRAF and MEK mutation inhibitors, based on the improved responses observed among patients harboring such mutations, many patients acquire therapeutic resistance and therefore do not achieve persistent, long-term responses (1). Antibodies specific for immune checkpoints, such as those targeting CTLA-4 or the PD1/PDL1 interaction, have also been approved by the FDA and have become a standard of care for patients with unresectable or metastatic melanoma; however, these therapeutic antibodies provide benefits to only some patients (2)
%U http://tcr.amegroups.com/article/view/21588/html